Form 4 holding
EVP, Access, Policy & Comms
Merck & Co., Inc.
- Security class
- Common Stock
- Shares / value
- 61,613
- Estimated value
- $7,411,443
- Report date
- 05 May 2026
- Price
- $120.29
- Ownership
- Direct
Chirfi Guindo
Insider Reports History
- Reporting-owner location
- Cambridge, MA
- Latest reporting-owner signature
-
By: /s/ Christine Bellon, Attorney-in-fact
Source: Latest parsed Forms 3/4/5 signature
- Transaction source note
- Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.
Identity
Names, identifiers, and filing context for this profile.
1 identity field
SEC source record
Original filing metadata and source links for verification.
1 source field
Source evidence
Original filing metadata and source links for verification.
1 source field
Reported holdings for Chirfi Guindo
Form 4 holding
EVP, Access, Policy & Comms
Merck & Co., Inc.
- Security class
- Restricted Stock Unit
- Shares / value
- 6,628
- Estimated value
- $3,256,690
- Report date
- 05 May 2026
- Price
- $88.25
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Head of Glob Prod Strat & Com
BIOGEN INC.
- Security class
- Restricted Stock Unit
- Shares / value
- 9,668
- Estimated value
- $2,313,456
- Report date
- 18 Feb 2022
- Price
- $239.29
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Head of Glob Prod Strat & Com
BIOGEN INC.
- Security class
- Common Stock
- Shares / value
- 7,364
- Estimated value
- $1,826,272
- Report date
- 18 Feb 2022
- Price
- $248.00
- Ownership
- Direct
Form 4 holding
Director
Beam Therapeutics Inc.
- Security class
- Stock Option (Right to Buy)
- Shares / value
- 19,676
- Estimated value
- $953,698
- Report date
- 03 Jun 2026
- Price
- $24.40
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
EVP, Access, Policy & Comms
Merck & Co., Inc.
- Security class
- Common Stock-401(k) Plan
- Shares / value
- 57
- Estimated value
- $6,873
- Report date
- 05 May 2026
- Price
- $120.29
- Ownership
- By 401(k)
Form 4 holding
EVP, Access, Policy & Comms
Merck & Co., Inc.
- Security class
- Stock Option (Right to Buy)
- Shares / value
- 19,402
- Estimated value
- Report date
- 05 May 2026
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Insider Reports Filed by Chirfi Guindo
4
BEAM
Beam Therapeutics Inc.
- Report period
- 03 Jun 2026
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 05 Jun 2026, 16:05
- Role
- Director
- Next action
- Open filing details
4
MRK
Merck & Co., Inc.
- Report period
- 05 May 2026
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 07 May 2026, 11:36
- Role
- EVP, Access, Policy & Comms
- Next action
- Open filing details
4
MRK
Merck & Co., Inc.
- Report period
- 29 Apr 2026
- Transactions
- 3
- Transaction value
- $0
- Accepted by SEC
- 01 May 2026, 18:54
- Role
- EVP, Access, Policy & Comms
- Next action
- Open filing details
4
MRK
Merck & Co., Inc.
- Report period
- 12 Feb 2026
- Transactions
- 1
- Transaction value
- -$1,214,562
- Accepted by SEC
- 12 Feb 2026, 16:02
- Role
- Chief Marketing Officer
- Next action
- Open filing details
4
MRK
Merck & Co., Inc.
- Report period
- 09 Feb 2026
- Transactions
- 1
- Transaction value
- -$1,184,101
- Accepted by SEC
- 09 Feb 2026, 16:04
- Role
- Chief Marketing Officer
- Next action
- Open filing details
4
MRK
Merck & Co., Inc.
- Report period
- 05 Feb 2026
- Transactions
- 1
- Transaction value
- -$2,437,676
- Accepted by SEC
- 06 Feb 2026, 16:10
- Role
- Chief Marketing Officer
- Next action
- Open filing details
4
MRK
Merck & Co., Inc.
- Report period
- 26 Jan 2026
- Transactions
- 1
- Transaction value
- +$1,059,501
- Accepted by SEC
- 28 Jan 2026, 16:08
- Role
- Chief Marketing Officer
- Next action
- Open filing details
4
MRK
Merck & Co., Inc.
- Report period
- 04 Aug 2025
- Transactions
- 3
- Transaction value
- +$1,484,943
- Accepted by SEC
- 05 Aug 2025, 08:43
- Role
- Chief Marketing Officer
- Next action
- Open filing details
4
BEAM
Beam Therapeutics Inc.
- Report period
- 04 Jun 2025
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 06 Jun 2025, 16:05
- Role
- Director
- Next action
- Open filing details
4
MRK
Merck & Co., Inc.
- Report period
- 29 Apr 2025
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 01 May 2025, 17:45
- Role
- Chief Marketing Officer
- Next action
- Open filing details
4
MRK
Merck & Co., Inc.
- Report period
- 27 Jan 2025
- Transactions
- 1
- Transaction value
- +$2,757,795
- Accepted by SEC
- 29 Jan 2025, 18:07
- Role
- Chief Marketing Officer
- Next action
- Open filing details
4
BEAM
Beam Therapeutics Inc.
- Report period
- 02 Dec 2024
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 04 Dec 2024, 07:22
- Role
- Director
- Next action
- Open filing details
3
BEAM
Beam Therapeutics Inc.
- Report period
- 02 Dec 2024
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 04 Dec 2024, 07:18
- Role
- Director
- Next action
- Open filing details
4
MRK
Merck & Co., Inc.
- Report period
- 05 Aug 2024
- Transactions
- 3
- Transaction value
- +$2,245,133
- Accepted by SEC
- 06 Aug 2024, 12:20
- Role
- Chief Marketing Officer
- Next action
- Open filing details
4
MRK
Merck & Co., Inc.
- Report period
- 30 Apr 2024
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 02 May 2024, 16:22
- Role
- Chief Marketing Officer
- Next action
- Open filing details
4
MRK
Merck & Co., Inc.
- Report period
- 03 Aug 2023
- Transactions
- 3
- Transaction value
- +$1,998,998
- Accepted by SEC
- 04 Aug 2023, 16:17
- Role
- Chief Marketing Officer
- Next action
- Open filing details
4
MRK
Merck & Co., Inc.
- Report period
- 02 May 2023
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 04 May 2023, 17:43
- Role
- Chief Marketing Officer
- Next action
- Open filing details
4
MRK
Merck & Co., Inc.
- Report period
- 03 Aug 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 04 Aug 2022, 16:04
- Role
- Chief Marketing Officer
- Next action
- Open filing details
3/A
MRK
Merck & Co., Inc.
- Report period
- 01 Jul 2022
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 28 Apr 2023, 16:18
- Role
- Chief Marketing Officer
- Next action
- Open filing details
4
BIIB
BIOGEN INC.
- Report period
- 18 Feb 2022
- Transactions
- 4
- Transaction value
- -$184,405
- Accepted by SEC
- 23 Feb 2022, 15:15
- Role
- Head of Glob Prod Strat & Com
- Next action
- Open filing details
4
BIIB
BIOGEN INC.
- Report period
- 12 Feb 2022
- Transactions
- 9
- Transaction value
- -$502,570
- Accepted by SEC
- 15 Feb 2022, 15:15
- Role
- Head of Glob Prod Strat & Com
- Next action
- Open filing details
4
BIIB
BIOGEN INC.
- Report period
- 10 Feb 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 14 Feb 2022, 15:26
- Role
- Head of Glob Prod Strat & Com
- Next action
- Open filing details
4
BIIB
BIOGEN INC.
- Report period
- 19 Jan 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 21 Jan 2022, 15:47
- Role
- Head of Glob Prod Strat & Com
- Next action
- Open filing details
4
BIIB
BIOGEN INC.
- Report period
- 07 Jun 2021
- Transactions
- 1
- Transaction value
- -$1,358,280
- Accepted by SEC
- 09 Jun 2021, 19:04
- Role
- Head of Glob Prod Strat & Com
- Next action
- Open filing details